Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Next Previous
Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Bial

    • Most Recent Events

    • 05 Dec 2017 Results of pooled post hoc analysis from three phase III trials (BIA-2093-301, -302 and -304), presented at the 71st Annual Meeting of the American Epilepsy Society.
    • 27 Jul 2017 Results of a post-hoc pooled analysis of safety data from NCT00957684, NCT00957047, NCT00957372 NCT00988429, NCT02281422, NCT02281526 and NCT01422720 studies published in the Drug Safety
    • 28 Apr 2017 Results assessing Indices of Thyroid Function in patients from six phase III studies and their extensions (BIA2093-301,302,304,045,046,050; n=1812), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top